Occlutech Prevails In U.k. Patent Appeal By Aga Medical

< BACK TO LEGAL starstarstarstarstar   People - Legal Press Release
24th June 2010, 11:53pm - Views: 376






Business Finance Occlutech GmbH 2 image







MEDIA RELEASE PR40167


Occlutech Prevails in U.K. Patent Appeal by AGA Medical


JENA, Germany, June 24, /PRNewswire-AsiaNet/ --


    In 2009 the Patents Court of the High Court, Chancery Division, decided

that Occlutech's range of Figulla ASD and PFO occluders do not infringe the 

U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against 

this decision. The U.K. Court of Appeal (civil division) in London announced 

its decision confirming that said Figulla ASD and PFO occluders do not 

infringe said patent.


    AGA asked for permission to appeal to the Supreme Court (formerly called

the House of Lords), but that application was refused. It is now open to AGA

to make an application direct to the Supreme Court for permission to appeal,

but permission is granted only sparingly, such as in cases that involve a

point of law of general public importance.


    Tor Peters, CEO of Occlutech says; "We are very happy with the courts

decision that again brings clarity to Occlutech's position that our unique

patented braiding technology is fundamentally different from the old

technology. The flexibility and versatility of our products and the

innovative delivery systems have helped us obtain market leading positions in

several markets and we intend to expand this position over the next years."


    Occlutech is a private company with R&D and manufacturing activities in

several European countries. Founded in 2003, the company sells its innovative

ASD and PFO occluders in over 40 countries, except Germany.


    Occlusion devices are used to treat structural heart disease,

including structural heart defects and abnormalities such as Atrial Septal

Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between

the heart's two atria, present in up to 25% of the population), in minimally

invasive, non-surgical procedures. The market for PFO occluders is expected

to expand significantly as the link between PFO and stroke, that is the third

most common cause of death, as well as severe migraine becomes increasingly

well documented.

    

    Tor Peters

    info@occlutech.de

    Tel: +49-3641-67-51-29


    Katrin Biedermann

    katrin.biedermann@occlutech.de

    Tel.: +49-3641-67-51-20


    Source: Occlutech GmbH








news articles logo NEWS ARTICLES
Contact News Articles |Remove this article